Vascepa's Current Approval Status
Vascepa (icosapent ethyl) gained FDA approval in 2012 for reducing triglyceride levels and expanded in 2020 via the REDUCE-IT trial for cardiovascular risk reduction in high-risk patients.[1] No ongoing approval process exists for new indications, as it's fully approved. Speeding up an already-complete process isn't applicable.
Could Expanded Indications Have Been Accelerated?
For its 2020 CV label expansion, Vascepa used standard supplemental New Drug Application (sNDA) pathways, not accelerated tracks like Fast Track, Breakthrough Therapy, or Priority Review, which can cut review times from 10 months to 6.[2] REDUCE-IT data was submitted in 2018; approval took about 20 months amid label disputes with the FDA over trial population claims.[3]
Standard Ways to Accelerate Similar Drug Approvals
FDA programs shorten timelines for urgent needs:
- Fast Track: For serious conditions with unmet needs; allows rolling reviews (e.g., 6-month target).
- Breakthrough Therapy: Mid/late-stage drugs showing substantial improvement; includes intensive FDA guidance.
- Priority Review: 6-month review vs. 10 for standard; granted if drug provides major advance.
- Accelerated Approval: Uses surrogate endpoints for serious diseases, with confirmatory trials post-market.
Amarin pursued none for Vascepa expansions, likely due to its non-oncology/rare disease profile.[2]
What Slowed Vascepa's Expansions?
Patent litigation and FDA negotiations delayed the 2020 label. Amarin sued the FDA in 2019 over restrictive wording, settling after approval.[3] Generic challenges (e.g., from Dr. Reddy's) focused on patents, not approval speed.[4]
Generic Entry and Market Competition
Vascepa faces generic competition post-patent expiry. Key patents expire 2033-2039, but FDA blocked some ANDAs until 2026 due to pediatric exclusivity.[4] No acceleration for generics; they follow standard Abbreviated New Drug Application (ANDA) reviews (10-15 months).
[1]: FDA.gov - Vascepa Approval History
[2]: FDA.gov - Expedited Programs
[3]: FDA.gov - REDUCE-IT Approval Summary
[4]: DrugPatentWatch.com - Vascepa Patents